Nordic presence in Portugal

Ascendis Pharma

Biopharmaceuticals (Lisbon)

Ascendis Pharma, the Hellerup-based biopharmaceutical company behind the TransCon technology platform, set up its own Portuguese company in October 2025: Ascendis Pharma Portugal, Unipessoal Lda (NIF 519052889), a Lisbon wholesaler of pharmaceutical products. Portugal sits in the “Iberia” cluster of the group’s Europe Direct sales model, and its first priority in the country is chronic hypoparathyroidism, the indication of its fastest-growing medicine, Yorvipath.

HeadquartersTuborg Boulevard 12, DK-2900 Hellerup, Denmark (Ascendis Pharma A/S, Nasdaq: ASND); president and CEO Jan Møller Mikkelsen
FoundedOperations began in December 2007 with the acquisition of Complex Biosystems GmbH, the company that invented the TransCon technologies
Employees (group)More than 1,100 worldwide (Jornal Económico, February 2026)
Revenue 2025€720.1 million, including Yorvipath €477.4 million and Skytrofa €206.2 million
Portuguese entityAscendis Pharma Portugal, Unipessoal Lda — NIF 519052889 — Rua Mar da China 3, 4.º andar, 1990-203 Lisboa; CAE 46460 (wholesale of pharmaceutical products); incorporated October 2025; listed as ASND Portugal, Unipessoal, Lda. (100%) in the 2025 Form 20-F
SectorBiopharmaceuticals — endocrinology rare diseases
DirectionDenmark → Portugal

Corridor footprint

Ascendis Pharma commercialises its approved Endocrinology Rare Disease products itself in selected countries, a set-up it calls “Europe Direct”. Its 2025 annual report on Form 20-F, filed with the US Securities and Exchange Commission on 11 February 2026, names six Europe Direct clusters — DACH, France & BeNeLux, Iberia (Portugal and Spain), Italy, the Nordics, and the UK & Ireland — and lists Portugal among the countries where the group has sales and representative offices, with Germany, France, Spain, Italy, Switzerland and the United Kingdom. The same filing lists ASND Portugal, Unipessoal, Lda. as a 100%-owned subsidiary, next to Ascendis Pharma Iberia S.L. in Spain. Group revenue reached €720.1 million in 2025, up from €363.6 million in 2024, driven by Yorvipath (€477.4 million).

The Lisbon company, now named Ascendis Pharma Portugal, Unipessoal Lda (NIF 519052889), is registered at Rua Mar da China 3, 4.º andar, 1990-203 Lisboa, with wholesale of pharmaceutical products (CAE 46460) as its activity. The business register shows its incorporation and the appointment of its officers in October 2025, two capital increases in March 2026 and a filing on its articles in May 2026. On 6 February 2026 Jornal Económico reported that Ascendis would enter the Portuguese market to bring into the National Health Service (SNS) a treatment for chronic hypoparathyroidism, a rare condition that causes low calcium and high phosphorus levels in the blood and for which, the paper said, no therapy replacing the missing hormone had been available in Portugal.

Why this matters for the corridor

Rather than licensing its products to a local distributor, Ascendis has built its own Portuguese company inside an Iberian cluster, the same direct model it uses in its home Nordic region. That makes Lisbon part of the commercial footprint of a Danish listed biotech whose revenue roughly doubled in 2025, and the pace at which SNS hospitals adopt Yorvipath — already the subject of a patient petition in 2026 — is the access question to watch.

Recent activity

Sources: Ascendis Pharma A/S annual report on Form 20-F for 2025 (SEC EDGAR, filed 11 February 2026); nif.pt and racius.com (NIF 519052889); Jornal Económico (6 February 2026); adti.pt (14 April 2026). Spotted an error? Email miguel@fractio.se.

Status: Compiled from public sources · Last verified: · Update this profile

Update this profile

Work at Ascendis Pharma? Send corrections or additions. Every update is checked before it is published; submissions are reviewed within a few working days.

Thinking about entering Portugal?

Fractio helps Nordic companies enter the Portuguese market — from market sizing to first sales, hiring, and legal setup.

Talk to Fractio →